Australia markets closed

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.00300.0000 (0.00%)
At close: 10:04AM AEDT
Full screen
Previous close0.0030
Open0.0030
Bid0.0030 x 10000000
Ask0.0040 x 249000000
Day's range0.0030 - 0.0030
52-week range0.0020 - 0.0080
Volume660,540
Avg. volume13,924,844
Market cap34.625M
Beta (5Y monthly)0.64
PE ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings date27 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation

    MELBOURNE, Australia, March 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the US launch of three (3) new diseases taking the total number of individual risk assessments included in the geneType Multi-Test to nine (9), all from the one simple saliva sample. This launch is in line with phase 2 rollout plan for the geneType Multi Risk-Test

  • GlobeNewswire

    Back-to-back Studies Validate geneType Breast Cancer Risk Test

    MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal Cancer Prevention Research. Highlights: 2nd published peer reviewed paper in the last month supporting the use of geneTyp

  • GlobeNewswire

    New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

    MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. Highlights: GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.The